Imatinib is an inhibitor of c-Kit, bcr-abl, and PDGFRA (platelet-derived growth factor receptor alpha), and it was used in a number of phase II studies enrolling patients with ACC. The gene discussed is PDGFRA; the disease is adrenal cortex carcinoma.